Nordea Investment Management AB Grows Holdings in Hologic, Inc. $HOLX

Nordea Investment Management AB lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,832,600 shares of the medical equipment provider’s stock after buying an additional 245,186 shares during the quarter. Nordea Investment Management AB’s holdings in Hologic were worth $190,067,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Chung Wu Investment Group LLC bought a new position in Hologic during the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd increased its position in shares of Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the last quarter. SJS Investment Consulting Inc. raised its stake in shares of Hologic by 341.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares in the last quarter. Loomis Sayles & Co. L P acquired a new stake in shares of Hologic in the 2nd quarter valued at about $33,000. Finally, Cromwell Holdings LLC lifted its position in shares of Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 436 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Hologic news, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the transaction, the director owned 47,336 shares in the company, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.88% of the company’s stock.

Hologic Price Performance

Shares of HOLX opened at $74.87 on Wednesday. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. The stock has a fifty day moving average price of $74.68 and a 200 day moving average price of $70.03. The company has a market cap of $16.69 billion, a P/E ratio of 30.19, a PEG ratio of 2.12 and a beta of 0.69.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the business posted $1.01 earnings per share. On average, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several research analyst reports. Argus cut Hologic from a “buy” rating to a “hold” rating in a research note on Monday. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, October 1st. BTIG Research reiterated a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a $78.00 target price on shares of Hologic in a report on Wednesday, October 22nd. Three equities research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and a consensus target price of $79.29.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.